Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -34.83% is 47% above its 2-year average of -65.94%, near the high end of its 2-year range (-105.17%–-27.60%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.55% above its 12-month average of -35.38%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -34.83%.
RETURN ON EQUITY (ROE)
-34.83%
RETURN ON EQUITY (ROE) AVG TTM
-35.38%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.55%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 547 covered companies
CURRENT VS SECTOR MEDIAN
+11.92%
vs the sector median at left
Jade Biosciences, Inc.
Market Cap
$828.00M
Return on Equity (ROE)
-34.83%
TTM Avg
-35.38%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$835.64M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$813.96M
Return on Equity (ROE)
-37.38%
TTM Avg
-29.74%
3Y Avg
-41.86%
5Y Avg
-72.28%
Market Cap
$804.16M
Return on Equity (ROE)
12.32%
TTM Avg
19.75%
3Y Avg
23.44%
5Y Avg
27.16%
Market Cap
$837.71M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$854.51M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$798.26M
Return on Equity (ROE)
-13.30%
TTM Avg
11.91%
3Y Avg
154.09%
5Y Avg
54.89%
Market Cap
$785.71M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $828.00M | -34.83% | -35.38% | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $835.64M | -97.08% | -96.94% | -22.72% | -22.72% |
| Ardelyx, Inc. (ARDX)vs › | $813.96M | -37.38% | -29.74% | -41.86% | -72.28% |
| Apnimed, Inc. (APMD)vs › | $805.62M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $804.16M | 12.32% | 19.75% | 23.44% | 27.16% |
| Beta Bionics, Inc. (BBNX)vs › | $837.71M | -28.46% | -48.75% | -33.66% | -33.66% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $854.51M | -33.06% | -24.59% | -41.17% | -18.72% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $798.26M | -13.30% | 11.91% | 154.09% | 54.89% |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | -16.56% | 0.55% | -10.56% | -13.37% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $875.38M | -24.02% | -108.12% | -89.93% | -68.76% |
ROE
-34.8%
ROA
-32.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -34.83% |
| 2026-03-31 | -43.72% |
| 2025-12-31 | -27.60% |
| 2024-12-31 | -91.15% |
| 2024-09-30 | -105.17% |
| 2024-06-30 | -93.16% |
